Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a development stage biotechnology company. The Company is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), an alpha-synucleinopathy. Its proprietary target discovery engine applies a thermodynamic, computational discovery platform - ProMIS and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product portfolio includes PMN310 / Amyloid-beta, PMN267 / TDP-43, and PMN442 / Alpha-synuclein. The Company plans to investigate additional synucleinopathies, including Parkinson's disease (PD) and dementia with Lewy bodies (DLB). Its wholly owned subsidiary is ProMIS Neurosciences (US) Inc.


NDAQ:PMN - Post by User

Bullboard Posts
Comment by farmerjaneon Feb 15, 2016 6:46pm
289 Views
Post# 24560154

RE:New update on PMN website

RE:New update on PMN websiteI hope you're right RC. Board and management owning 20.8 % fully diluted, they certainly have padded themselves with options.

Lots of praise for the new management team, but i have not seen any solid news to date ? To hire marketing team to promote they have patents seems a bit ridiculous to me, announcing patents over the last 7-8 years haven't bought them anything. Could have been a false front.

May-be the some preliminary news on In-Vitro Validation will be the jump start. I noticed in their corporate update that "In-Vitro validation with Brain tissue of AD pataients, target completion in Q2- goal to  show bilogical proof of concept - prion selectivity, positive findings would substantiate our likely differentiation".

They probably did this already in Cashman's lab, they new of their target early last year will before they patented it. It does not take long for mouse studies ? I'm sure Cashman knows the answers to these ?

Last report, said they had money till the second quarter, getting close, i can till you one thing if they try and pull a fast one and raise the 2MM as their update says at these levels, i will be asking the securities commission to investigate "Cashman's Lab", this could put far to much ownership in the BOD, and would be a scam if they do this ? 

Hope it does not get to this, but do you folks in Edmonton want to remind me what you were told last May ? 
Bullboard Posts